Drug Trial Radar · NCT00729469
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
Last checked: Nov 20, 2026Latest source record: May 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
919
Actual
Start
Jul 2008
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- Collaborators
- Hormos Medical; QuatRx Pharmaceuticals
- First posted
- Aug 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of ospemifene in postmenopausal women experiencing moderate to severe vaginal dryness and vaginal pain associated with sexual activity.
Conditions
- Atrophy
- Vaginal Diseases
Interventions
Ospemifene 60 mgDrug
60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
PlaceboDrug
oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear (Dryness Strata)Time frame: 12 weeks
- Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smears (Dryness Strata)Time frame: 12 weeks
- Change From Baseline to Week 12 in Vaginal pH (Dryness Strata)Time frame: 12 weeks
- Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness Associated With Sexual Activity (Dryness Strata)Time frame: 12 weeks
- Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear (Dyspareunia Strata)Time frame: 12 weeks
- Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smears (Dyspareunia Strata)Time frame: 12 weeks
- Change From Baseline to Week 12 in Vaginal pH (Dyspareunia Strata)Time frame: 12 weeks
- Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Pain Associated With Sexual Activity (Dyspareunia Strata)Time frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.